артериальное давление, антигипертензивный препарат, фактор активации тромбоцитов, Medicine

The study describes the synthesis and hypotensive effects of stable platelet activation factor (PAF) precursor 1-hexadecyl-2-m ethylcarbamoyl-phosphatidic acid (HMCP) оn outbred Wistar rats with 1-kidney 1-clip (1K1C) renovascular hypertension. Intravenous injection of 0.1, 0.5, 1 and 5 mg/kg HMCP resulted in a sharp decline of up to 50% of MAP with subsequent restoration to initial level. In some hypertensive 1K1C rats HMCP has a prolonged effect with blood pressure stabilized at 75% of initial level after 30 min post injection. HMCP was toxic at higher doses with a LD50 around 3 mg/kg.